keyword
https://read.qxmd.com/read/33045822/peptide-and-pseudo-peptide-psma-cu-64-radiopharmaceuticals
#1
Siroos Mirzaei, Rainer W Lipp
In recent years, the introduction of theranostic twins for specific diagnosis and treatment in patients with neuroendocrine tumors became a nuclear medicine success story. 64Cu/18F labeled prostate specific membrane antigen (PSMA) for molecular imaging with PET-CT and peptide radioligand therapy with 177Lu labeled PSMA inhibitors will favorably become the next theranostic twins in nuclear medicine history. 68Ga/ 64Cu/18F PSMA PET/CT detects metastatic prostate cancer with high diagnostic sensitivity and specificity...
October 12, 2020: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://read.qxmd.com/read/33037409/microrna-determinants-of-neuroendocrine-differentiation-in-metastatic-castration-resistant-prostate-cancer
#2
Divya Bhagirath, Michael Liston, Nikhil Patel, Theresa Akoto, Byron Lui, Thao Ly Yang, Dat My To, Shahana Majid, Rajvir Dahiya, Z Laura Tabatabai, Sharanjot Saini
Therapy-induced neuroendocrine prostate cancer (NEPC), an extremely aggressive variant of castration-resistant prostate cancer (CRPC), is increasing in incidence with the widespread use of highly potent androgen receptor (AR)-pathway inhibitors (APIs) such as Enzalutamide (ENZ) and Abiraterone and arises via a reversible trans-differentiation process, referred to as neuroendocrine differentiation (NED). The molecular basis of NED is not completely understood leading to a lack of effective molecular markers for its diagnosis...
October 9, 2020: Oncogene
https://read.qxmd.com/read/33037092/combination-strategies-to-improve-targeted-radionuclide-therapy
#3
Tiffany Chan, Edward O'Neill, Christine Habjan, Bart Cornelissen
In recent years, targeted radionuclide therapy (TRT) has emerged as a promising strategy for cancer treatment. In contrast to conventional radiotherapy, TRT delivers ionising radiation to tumours in a targeted manner, reducing the dose that healthy tissues are exposed to. Existing TRT strategies include the use of 177 Lu-DOTATATE and 131 I-MIBG, FDA-approved agents for the treatment of neuroendocrine tumours, and 177 Lu-PSMA, which is being investigated for the treatment of prostate cancer. Although promising results have been obtained with these agents, clinical evidence acquired to date suggests that only a small percentage of patients achieve complete response...
October 9, 2020: Journal of Nuclear Medicine
https://read.qxmd.com/read/33031248/an-incidental-uptake-of-18f-choline-at-pet-ct-in-gastric-neuroendocrine-tumor
#4
Laura Evangelista, Gianluca Cassarino, Decio Capobianco, Michele Povolato, Serena Battista, Marco Rensi
We present a case of neuroendocrine tumor localized in the gastric mucosa, incidentally detected by F-choline PET/CT in a 69-year-old man with prostate cancer. F-choline PET/CT scan showed an increased activity in the stomach, later diagnosed as a well-differentiated neuroendocrine tumor, at biopsy. A careful attention of reading F-choline PET/CT images should be made, in order to avoid the missing of potential concomitant neoplasia in patients with prostate cancer.
October 7, 2020: Clinical Nuclear Medicine
https://read.qxmd.com/read/33029516/the-correlation-between-psca-expression-and-neuroendocrine-differentiation-in-prostate-cancer
#5
Qian Xiang, Zhiguo Zhu, Lianmin Luo, Jiamin Wang, Yangzhou Liu, Yihan Deng, Mingda Zhou, Zhigang Zhao
The prostate stem cell antigen (PSCA), as a predominantly prostate-specific marker, is overexpressed in most prostate cancer specimens, is positively correlated with prostate cancer androgen independence, and has the potential to be treated with castration-resistant prostate cancer (CRPC) as a gene therapy target. Using the typical androgen deprivation therapy, most tumors will progress to CRPC, as well as develop into neuroendocrine prostate cancer (NEPC) characterized by the expression of neuroendocrine markers such as enolase 2 (NSE)...
2020: BioMed Research International
https://read.qxmd.com/read/33015525/dickkopf-1-can-lead-to-immune-evasion-in-metastatic-castration-resistant-prostate-cancer
#6
David R Wise, Jeffrey A Schneider, Joshua Armenia, Victor Adorno Febles, Bridget McLaughlin, Ryan Brennan, Katie L Thoren, Wassim Abida, Karen S Sfanos, Angelo M De Marzo, Srinivasan Yegnasubramanian, Josef J Fox, Michael Haas, Heidi Heath, Michael H Kagey, Walter Newman, Cynthia A Sirard, Martin Fleisher, Michael J Morris, Yu Chen, Steven M Larson, Michael C Haffner, Peter S Nelson, Nikolaus Schultz, Michael J Garabedian, Howard I Scher, Susan K Logan, Charles L Sawyers
PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) with low androgen receptor (AR) and without neuroendocrine signaling, termed double-negative prostate cancer (DNPC), is increasingly prevalent in patients treated with AR signaling inhibitors and is in need of new biomarkers and therapeutic targets. METHODS: Candidate genes enriched in DNPC were determined using differential gene expression analysis of discovery and validation cohorts of mCRPC biopsies...
2020: JCO Precision Oncology
https://read.qxmd.com/read/33009820/histone-demethylase-phf8-drives-neuroendocrine-prostate-cancer-progression-by-epigenetically-upregulating-foxa2
#7
Qiuli Liu, Jian Pang, Lin-Ang Wang, Zhuowei Huang, Jing Xu, Xingxia Yang, Qiubo Xie, Yiqiang Huang, Tang Tang, Dali Tong, Gaolei Liu, Luofu Wang, Dianzheng Zhang, Qiang Ma, Hualiang Xiao, Weihua Lan, Jun Qin, Jun Jiang
Neuroendocrine prostate cancer (NEPC) is a more aggressive subtype of castration-resistant prostate cancer (CRPC). Although it is well established that PHF8 can enhance prostate cancer cell proliferation, whether PHF8 is involved in prostate cancer initiation and progression is relatively unclear. By comparing the transgenic adenocarcinoma of the mouse prostate (TRAMP) mice with or without Phf8 knockout, we systemically examined the role of PHF8 in prostate cancer development. We found that PHF8 plays a minimum role in initiation and progression of adenocarcinoma...
October 3, 2020: Journal of Pathology
https://read.qxmd.com/read/33009488/de-novo-induction-of-lineage-plasticity-from-human-prostate-luminal-epithelial-cells-by-activated-akt1-and-c-myc
#8
Oh-Joon Kwon, Li Zhang, Deyong Jia, Zhicheng Zhou, Zhouyihan Li, Michael Haffner, John K Lee, Lawrence True, Colm Morrissey, Li Xin
Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that either develops de novo or arises from prostate adenocarcinoma as a result of treatment resistance. Although the prostate basal cells have been shown to directly generate tumor cells with neuroendocrine features when transduced with oncogenic signaling, the identity of the cell-of-origin for de novo NEPC remains unclear. We show that the TACSTD2high human prostate luminal epithelia cells highly express SOX2 and are relatively enriched in the transition zone prostate...
October 2, 2020: Oncogene
https://read.qxmd.com/read/33000273/n%C3%A2-myc-induces-the-tumor-progression-of-prostate-cancer-by-regulating-fscn1
#9
Guifang He, Mingfeng Li, Linna Fang, Lingfan Xu, Xiaojuan Huang, Lulu Zheng, Lijie Yang, Wenwu Luo, Yongping Cai, Wei Ma, Chaozhao Liang, Yu Yin
The oncoprotein N‑Myc has a carcinogenic effect in numerous types of cancer, and it can cause castration resistance in prostate cancer (PCa), and leads to the development of small cell neuroendocrine cancer by regulating multiple target genes. Immunohistochemical staining, RT‑qPCR, western blotting, wound healing and CCK‑8 assays were used to detect the expression of N‑Myc and FSCN1 as well as AR and CgA at the human level and cell level. The immunohistochemical results revealed that the protein levels of N‑Myc proto‑oncogene protein (N‑Myc) and fascin (FSCN1) in PCa were significantly higher than that of hyperplastic tissues (P<0...
November 2020: Oncology Reports
https://read.qxmd.com/read/32963351/egfr-upregulated-lifr-promotes-suclg2-dependent-castration-resistance-and-neuroendocrine-differentiation-of-prostate-cancer
#10
Shian-Ren Lin, Yu-Ching Wen, Hsiu-Lien Yeh, Kuo-Ching Jiang, Wei-Hao Chen, Ntlotlang Mokgautsi, Jiaoti Huang, Wei-Yu Chen, Yen-Nien Liu
Neuroendocrine (NE) differentiation is a well-recognized phenotypic change of prostate cancer after androgen deprivation therapy (ADT), and it ultimately develops into an aggressive subset of this disease. However, the contribution of signaling pathways that lead to metabolic disorders and NE differentiation of prostate cancer remains unclear. In this study, we identified that ADT induced upregulation of the succinate-CoA ligase GDP-forming beta subunit (SUCLG2), which regulates succinate metabolism and NE differentiation of prostate cancer...
September 22, 2020: Oncogene
https://read.qxmd.com/read/32922691/small-extracellular-vesicles-modulated-by-%C3%AE-v%C3%AE-3-integrin-induce-neuroendocrine-differentiation-in-recipient-cancer-cells
#11
Fabio Quaglia, Shiv Ram Krishn, George G Daaboul, Srawasti Sarker, Raffaella Pippa, Josep Domingo-Domenech, Gaurav Kumar, Paolo Fortina, Peter McCue, William K Kelly, Himisha Beltran, Qin Liu, Lucia R Languino
The ability of small extracellular vesicles (sEVs) to reprogram cancer cells is well established. However, the specific sEV components able to mediate aberrant effects in cancer cells have not been characterized. Integrins are major players in mediating sEV functions. We have previously reported that the αVβ3 integrin is detected in sEVs of prostate cancer (PrCa) cells and transferred into recipient cells. Here, we investigate whether sEVs from αVβ3-expressing cells affect tumour growth differently than sEVs from control cells that do not express αVβ3...
May 24, 2020: Journal of Extracellular Vesicles
https://read.qxmd.com/read/32900357/theranostics-of-metastatic-prostate-cancer-applying-64cu-18f-68ga-psma-pet-ct-and-177lu-radiopharmaceuticals
#12
Siroos Mirzaei, Fairoz Mohammed, Shahin Zandieh
The successful use of theranostic twins in neuroendocrine tumors (NET) was the pioneering approach to radionuclide therapy in other tumor types. 64Cu/18F PSMA for molecular imaging with PET-CT and peptide radioligand therapy (PRLT) with 177Lu labeled PSMA inhibitors are the next theranostic twins in nuclear medicine. 68Ga/ 64Cu/18F PSMA PET-CT detects metastatic prostate cancer with high diagnostic sensitivity and specificity and can be used to select patients for PRLT and evaluate therapy response. Radionuclide therapy with 177Lu-PSMA inhibitors has been shown to be effective in the treatment of metastatic CRPC...
September 8, 2020: Current Radiopharmaceuticals
https://read.qxmd.com/read/32895469/a-simple-quantitative-pcr-assay-to-determine-tramp-transgene-zygosity
#13
Ruidong Chen, Xin Liang, Mollianne M Murray, Ellen Karasik, Jenny J Han, Ming Zhu, Barbara A Foster, Daniel E Frigo, Guocan Wang
BACKGROUND: The TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model remains one of the most widely used transgenic mouse models of prostate cancer. This is due to its ability to recapitulate with ~100% penetrance multiple aspects of the human disease such as prostatic intraepithelial neoplasia lesions, invasive carcinoma, progression to castration-resistant prostate cancer including aggressive neuroendocrine prostate cancer and metastasis. Despite its popularity, the use of TRAMP mice is limited/slowed by the inability to distinguish the zygosity of the TRAMP transgene...
September 7, 2020: Prostate Cancer and Prostatic Diseases
https://read.qxmd.com/read/32867540/dynamics-of-the-cell-free-dna-methylome-of-metastatic-prostate-cancer-during-androgen-targeting-treatment
#14
Madonna R Peter, Misha Bilenky, Ruth Isserlin, Gary D Bader, Shu Yi Shen, Daniel D De Carvalho, Aaron R Hansen, Pingzhao Hu, Neil E Fleshner, Anthony M Joshua, Martin Hirst, Bharati Bapat
Aim: We examined methylation changes in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC) during treatment. Patients & methods: Genome-wide methylation analysis of sequentially collected cfDNA samples derived from mCRPC patients undergoing androgen-targeting therapy was performed. Results: Alterations in methylation states of genes previously implicated in prostate cancer progression were observed and patients that maintained methylation changes throughout therapy tended to have a longer time to clinical progression...
September 1, 2020: Epigenomics
https://read.qxmd.com/read/32862212/covid-19-pandemic-implications-for-radionuclide-therapy-in-nuclear-medicine-departments
#15
S Koukouraki, N Kapsoritakis, O Bourogianni
The global COVID-19 health and economic crisis has forced people to adopt challenging rules of social distancing and self-isolation. Health care staff has been advised to change working routines to keep themselves and their patients safe. Radionuclide therapy has had an increasing role in clinical practice. Most therapeutic radionuclide procedures have applications in oncology. Cancer patients are an especially fragile and vulnerable population with higher risk due to co morbidities and immunosuppression. COVID-19 is another risk that must be considered in treatment planning...
May 2020: Hellenic Journal of Nuclear Medicine
https://read.qxmd.com/read/32860394/covid-19-pandemic-implications-for-radionuclide-therapy-in-nuclear-medicine-departments
#16
S Koukouraki, N Kapsoritakis, O Bourogianni
The global COVID-19 health and economic crisis has forced people to adopt challenging rules of social distancing and self-isolation. Health care staff has been advised to change working routines to keep themselves and their patients safe. Radionuclide therapy has had an increasing role in clinical practice. Most therapeutic radionuclide procedures have applications in oncology. Cancer patients are an especially fragile and vulnerable population with higher risk due to co morbidities and immunosuppression. COVID-19 is another risk that must be considered in treatment planning...
May 2020: Hellenic Journal of Nuclear Medicine
https://read.qxmd.com/read/32853681/recommendations-for-the-use-of-next-generation-sequencing-ngs-for-patients-with-metastatic-cancers-a-report-from-the-esmo-precision-medicine-working-group
#17
REVIEW
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam, N Wagle, A Stenzinger, J Bonastre, A Bayle, S Michiels, I Bièche, E Rouleau, S Jezdic, J-Y Douillard, J Reis-Filho, R Dienstmann, F André
Next-generation sequencing (NGS) allows sequencing a high number of nucleotides in a short time frame at an affordable cost. While this technology has been widely implemented, there are no recommendations from scientific societies about their use in oncology practice. The European Society for Medical Oncology (ESMO) is proposing three levels of recommendations for the use of NGS. Based on the current evidence, ESMO recommends routine use of NGS on tumour samples in advanced non-squamous NSCLC, prostate cancers, ovarian cancers and cholangiocarcinoma...
July 28, 2020: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/32848424/metastatic-castration-resistant-prostate-cancer-with-neuroendocrine-transformation-and-brca-1-germ-line-mutation-a-case-report-and-literature-review
#18
Yinhang Wu, Yongsheng Gao, Xue Dou, Jinbo Yue
A 63-year-old man with a significantly high prostate-specific antigen level was diagnosed via pathology to have advanced prostate adenocarcinoma due to multiple lung metastases. He was then treated with androgen deprivation therapy (ADT) comprising bicalutamide and goserelin. Only after 6 months of stable disease, the cancer progressed and the drug was changed to abiraterone; however, no significant therapeutic effect was observed and the disease was considered as castration-resistant prostate cancer. The histopathologic analysis of the biopsied metastatic lymph node confirmed small-cell neuroendocrine carcinoma, and genetic testing revealed BRCA1 germ-line mutation...
2020: OncoTargets and Therapy
https://read.qxmd.com/read/32833943/impact-of-a-prior-nonpancreatic-malignancy-on-survival-outcomes-of-patients-with-stage-iv-pancreatic-neuroendocrine-tumor-a-population-based-and-propensity-score-matching-study
#19
Gang Li, Mao-Lin Tian, Yun-Tao Bing, Chun-Hui Yuan, Dian-Rong Xiu
OBJECTIVE: The aim of the study was to investigate the impact of a previous nonpancreatic malignancy on the survival outcomes in patients with a stage IV pancreatic neuroendocrine tumor (PanNET). METHODS: The Surveillance, Epidemiology, and End Results database was reviewed, and patients diagnosed with a stage IV PanNET between 2004 and 2015 were selected. Patients were divided into 2 groups according to the presence or absence of a previous nonpancreatic malignancy...
September 2020: Pancreas
https://read.qxmd.com/read/32829355/-efficacy-of-amrubicin-monotherapy-for-patients-with-extrapulmonary-neuroendocrine-carcinomas-refractory-to-platinum-based-chemotherapy
#20
Chikako Funasaka, Yusuke Kanemasa, Akihiko Kageyama, Tatsu Shimoyama, Yasushi Omuro
Standard regimens for extrapulmonary neuroendocrine carcinomas(EPNEC)are not established. Treatment used for small cell lung cancer is also used for EPNECs. Amrubicin(AMR) monotherapy is used as salvage therapy for small cell lung cancer, but its efficacy in EPNEC is not clear. The aim of this study was to estimate the efficacy of AMR monotherapy in EPNEC. We retrospectively investigated patients with EPNEC who received first-line platinum-based chemotherapy between April 2007 and March 2019. The time to treatment failure(TTF)and the efficacy and toxicity was analyzed in the patients who received AMR monotherapy...
August 2020: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
83546
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"